Tag: interleukin 6 (IL-6)

1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic ...

1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated ...

Immune-checkpoint inhibitors (ICIs) have significantly improved outcomes in a variety of malignancies. Immune-related adverse events, however, are common and may ...